Piper Sandler downgraded Esperion (ESPR) to Neutral from Overweight with a price target of $3.16, down from $9, after funds managed by Archimed announced a deal to acquire Esperion for $3.16 per share in cash at closing, plus the right to participate in contingent milestone payments of up to $100M in the aggregate tied to future net sales performance.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ESPR:
- Esperion agrees to $1.1 billion ARCHIMED buyout
- Midday Fly By: Apple reports Q2 beat, oil majors post mixed results
- Esperion downgraded to Neutral from Buy at H.C. Wainwright
- Esperion downgraded to Neutral from Overweight at Cantor Fitzgerald
- Esperion to be acquired by Archimed for $3.16 per share, one CVR